Description
Lorem ipsum dolor sit amet consectetur adipiscing elit sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam quis nostrud.
Client:
Chad Wildermuth
Category:
Portfolio
Date:
December 10, 2018
-
Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting
27 May, 2022
-
Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer
23 May, 2022
-
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting
17 February, 2022